SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001558370-21-012901
Filing Date
2021-09-30
Accepted
2021-09-30 16:30:44
Documents
5
Period of Report
2021-11-24

Document Format Files

Seq Description Document Type Size
1 DEF 14A tmb-20211124xdef14a.htm DEF 14A 160463
2 GRAPHIC tmb-20211124xdef14a003.jpg GRAPHIC 8711
3 GRAPHIC tmb-20211124xdef14a013.jpg GRAPHIC 69827
4 GRAPHIC tmb-20211124xdef14a012.jpg GRAPHIC 56354
5 GRAPHIC tmb-20211124xdef14a004.jpg GRAPHIC 15078
  Complete submission text file 0001558370-21-012901.txt   368857
Mailing Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601
Business Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601 201-696-9345
Protalix BioTherapeutics, Inc. (Filer) CIK: 0001006281 (see all company filings)

IRS No.: 650643773 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-33357 | Film No.: 211295401
SIC: 2836 Biological Products, (No Diagnostic Substances)